CEPI, the Coalition for Epidemic Preparedness Innovations, yesterday announced a $43.5 million deal with pharmaceutical giant AstraZeneca to advance the development of a novel antibody that could ...

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) ...

de-risked pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique Biologics CDMO providing biological drug development ...

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and contract development and manufacturing (CDMO) services, ...

at around 25 kDA and Bivalent camelid VHH around 30 kDA. The small size allows for high transduction efficiency and CAR positivity, allowing a low total cell dose. With no disulfide bonds and a ...

The FDA thinks an antibody-drug conjugate (ADC) developed by AbbVie could set new standards in treatment for certain patients with lung cancer, awarding the drug breakthrough status. Teliso-V ...

In the study, published in the journal Nature Medicine¸ older adults who were exposed to seasonal flu viruses that circulated before 1968 were found to be more likely to have antibodies that bind to ...

After hours: March 18 at 6:45:25 PM EDT Loading Chart for IBIO ...

Center for Cancer Diagnosis and Treatment, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province 215000, China ...